Skip to content
Riskpilot
← Tilbage til søgning
Log ind
Få fuld adgang
ApoXcel AB
AB
Active
Org 5593341497
Kvarngatan 23, 692 34
Kumla
Retail sale of pharmaceutical products
·
NACE 4773
Est. 2021 · 4 years old
1-4 employees
Overvåg
Share
Sweden
/
Companies
/
Retail sale of pharmaceutical products
/
ApoXcel AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
6M
12M
17M
23M
4M
2022
11M
2023
20M
2024
EBITDA
SEK millions
1M
1M
1M
0M
0M
0M
2022
0M
0%
2023
1M
+100%
2024
Income statement
SEK thousands
Item
2022
2023
2024
Revenue
3 582
11 069
20 357
Staff expenses
−686
−971
−1 441
EBITDA
−437
417
1 491
Depreciation & amort.
−104
−273
−273
EBIT
−541
144
1 218
Net financials
−110
−245
−182
Profit before tax
—
0
1 011
Tax
—
—
−79
Net profit
−651
0
932
Balance sheet
SEK thousands
Item
2022
2023
2024
Total assets
3 462
4 754
6 161
Equity
349
349
1 281
Long-term debt
1 478
1 274
789
Short-term debt
1 635
3 130
4 091
Total debt
3 112
4 404
4 880
Financial ratios
5-year trend
EBITDA-margin
7.3%
This company
15.8%
Market median
-54% vs market
2022
2024
Soliditetsgrad
20.8%
This company
38.2%
Market median
-46% vs market
2022
2024
Egenkapitalforrentning
72.7%
This company
18.4%
Market median
+295% vs market
2022
2024
Nettoresultatgrad
4.6%
This company
8.1%
Market median
-43% vs market
2022
2024
Aktivomsætning
3.30×
This company
1.12×
Market median
+195% vs market
2022
2024
Gæld/egenkapital
3.81×
This company
0.62×
Market median
-515% vs market
2022
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2021-09-08 – 2022-12-31
View
PDF
More on ApoXcel AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
